An investigation of the effects of intranasal oxytocin spray on socio-emotional brain regions in ageing in healthy adults.
Australian Catholic University Research
140 participants
Oct 20, 2015
Interventional
Conditions
Summary
The overall aim of the current study is to examine social and emotional brain regions involved in healthy ageing using a double-blind placebo controlled intranasal oxytocin design and MRI techniques involving fMRI.
Eligibility
Inclusion Criteria1
- Right-handed; non-smoker and no drug/alcohol abuse; medication free; no neurological disorders, and no metal objects present in body (or which can't be removed or which is not MRI safe).
Exclusion Criteria1
- Clinically significant medical or neurological condition, significant head injury (or loss of consciousness from longer than 5 mins), presence of ferrous-containing metals within the body, inability to tolerate small enclosed spaces without anxiety.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Two acute treatment (24 IU each) conditions including; a) intranasal placebo, and b) intranasal oxytocin (Syntocinon, Novartis, Switzerland). The two treatment conditions will be separated by a minimum of 1 week (washout period). The nasal sprays will be administered 50 mins prior to the functional magnetic resonance (fMRI) protocol using a standard supervised dosage procedure that involves 3 sprays in each the left or right nostril (6 sprays total). The fMRI protocol will be 20mins in duration and involve showing participants a brief task involving pictures of human faces expressing different emotions. The MRI protocol will also involve taking structural, resting state images of the brain while the participant is not engaged in a task.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12615001148561